Thera-SAbDab

VORSETUZUMAB

>   Structural Summary
TherapeuticVorsetuzumab
TargetCD70
Heavy ChainQVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLKWMGWINTYTGEPTYADAFKGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDYGDYGMDYWGQGTTVTVSS
Light ChainDIVMTQSPDSLAVSLGERATINCRASKSVSTSGYSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQHSREVPWTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb ADC
IsotypeG1
Highest Clinical Trial (October '21)Phase-II
Estimated Status (October '21)Discontinued
Recorded Developmental Technologyna
INN Year Proposed2012
INN Year Recommended2013
Companies InvolvedSeattle Genetics
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAutoimmune disorders, Cancer, Inflammation, Plaque psoriasis
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy